Bullous pemphigoid is a “frustrating” chronic ... It’s an autoimmune disease, meaning it’s a malfunction in the immune system, but there isn’t one clear cause. “It’s not specifically ...

and the latest to be reviewed could throw a lifeline to patients with a rare and debilitating autoimmune disease affecting the skin. Bullous pemphigoid (BP), which has no FDA-approved targeted ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo ...

“By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce ...

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD | Regulatory News ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease ...